Quoin pharmaceuticals announces further clinical evidence of qrx003 effectiveness in netherton syndrome

Ashburn, va., jan. 23, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of the potential efficacy of qrx003 in netherton syndrome.

QNRX Ratings Summary

QNRX Quant Ranking